2019
Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Gonsalves W, Devarakonda S, Baz R, Neparidze N, Adjei A, Kunos C, Kumar S. Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma. Blood 2019, 134: 3160. DOI: 10.1182/blood-2019-123399.Peer-Reviewed Original ResearchMitochondrial respirationNormal protein homeostasisProteasome inhibitorsTricarboxylic acid cycleProtein homeostasisProteotoxic stressC-myc activationCellular bioenergeticsGenomic DNATCA cycleMolecular strategiesCellular respirationAcid cycleCell deathGlutamine metabolismImmunoglobulin proteinGlutaminase inhibitorMM cellsProteasome inhibitionIncrease of glutamineResistance mechanismsCell linesCancer cellsCB-839Human myeloma cell lines
2009
Waldenstrom's macroglobulinemia: Recent advances in biology and therapy.
Neparidze N, Dhodapkar MV. Waldenstrom's macroglobulinemia: Recent advances in biology and therapy. Clinical Advances In Hematology And Oncology 2009, 7: 677-81, 687-90. PMID: 20040909, PMCID: PMC3612541.Peer-Reviewed Original ResearchConceptsWaldenstrom's macroglobulinemiaLymphoplasmacytic cellsClonal lymphoplasmacytic cellsHigh-dose chemotherapyBone marrow infiltrationInternational Staging SystemStem cell transplantationB-cell disordersComplete remissionFrontline therapyObjective responseMarrow infiltrationCell transplantationStaging systemTherapeutic armamentariumMonoclonal gammopathyNovel agentsMacroglobulinemiaTherapyProteasome inhibitorsDisease biologyNucleoside analoguesPromising activityRecent studiesRecent advances